Robust Appetite For Biosolution IPO As OA Cell Therapy Nears Commercialization

Biosolution's IPO, which was priced at the high end of the range despite dampened biotech sentiment following the arrest of Nature Cell's CEO, is poised to help accelerate commercialization of the South Korean cell therapy company's osteoarthritis treatment CartiLife and the progress of other pipeline assets.

South Korea — Biosolution IPO draws strong interest • Source: Shutterstock

Amid the expected approval of the company's novel osteoarthritis therapy, investors showed a strong appetite for Biosolution Co. Ltd.'s initial public offering on Aug. 9-10, helping the South Korean cell therapy venture to raise KRW43.5bn ($38.5m).

The company priced 1.5 million common shares at KRW29,000 each in the IPO, which was at the top end of...